This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
Capital at risk
overfunded
NowRx
  • Equity
  • USA USA
1558%
Raised
£5,312,390
Investors
895
Target
£340,900
Equity
25.96%
Pre-money valuation
£15,151,515

NowRx is a new model for pharmacy utilizing robotics, software automation and logistics to provide free same day delivery of prescription medications in the USA. Launched in Silicon Valley in 2016, the company has delivered 28,000 prescriptions to 5,900 customers and generated $3 million in revenue.

  • 2017 revenues were $2.49m, an increase of 273.5% as compared to 2016
  • The first app approved to fill prescriptions on Google Home
  • More than 1,300 referring physicians, an increase of 140% over 2016
  • $2 million already invested in current round
Information The company is incorporated and based in the USA. The progress bar above includes £4,958,460 raised via a concurrent offering being conducted abroad. Investments are for a beneficial interest in equity in this US-based company that will be held on behalf of Investors by a Nominee. Investors agree to the Subscription Agreement and its accompanying exhibits in the documents section below. The Subscription Agreement contains certain representations and warranties to NowRX Inc. See the Investment FAQ's and Legal Explanation Document for more details including exchange rate explanation. Investors should seek their own tax advice regarding investment in US securities.

Idea

Traditional retail pharmacy is inconvenient and time-consuming. The large pharmacy chains have historically focused on in-store pickup of prescription medications, attracting customers into large stores filled with other products (vitamins, beauty products, food etc). We believe the large pharmacy chains are ill-equipped to develop the necessary technology, logistics and customer service processes to meet customers demand for convenience, and furthermore, they are incentivized against free same-day home delivery.

We re-conceive retail pharmacy by establishing highly automated, local warehouse facilities within customer communities to provide free same-day delivery of medications and over-the-counter items to the customer. NowRx leverages the latest in robotics, software automation and logistics to provide the most convenient customer experience available. By removing the dependency on large retail stores, NowRx operates with significantly lower fixed overhead expenses and can absorb delivery costs so the customer doesn't have to.

Retail pharmacy is a $280 billion industry in the US and $1 trillion globally. We believe the bulk of this market will soon be forced to adopt the same free same-day delivery model. Pressure continues to mount on industry players to make strategic build vs. buy decisions to address this new reality.

Disclosures: company has loans, 2017 net loss was $1.09m

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS.  CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
 
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest.  The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan.  There will be no public offering of the Securities in the United States.
 
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7.  Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear.  Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
 
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.  Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company.  Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
 
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.

To see the rest of the NowRx pitch, join now.
It’s free, quick and easy.

Join

Already registered? Log in

To see the rest of the NowRx pitch, join now.
It’s free, quick and easy.

NowRx

Join to read more information about the NowRx team, documents, and what other investors are saying about the pitch.

If you choose to invest we won’t take your money until the pitch closes and you can cancel your investment at any time.

Crowdcube is a leading investment crowdfunding platform

Successfully Invested
£689m+
Registered Investors
735k+